Autogene cevumeran goes on hold in adjuvant bladder cancer.
ApexOnco Front Page
Recent articles
The deal for ISB 2001 is worth $700m up front.
Adverse events will be closely watched when full data are reported.
Regeneron is facing two FDA decisions for its T-cell engagers.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
The Avanzar study could read out shortly.
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
